Live cell imaging is a powerful method to study protein dynamics at the cell surface, but conventional imaging probes are bulky, or interfere with protein function 1,2 , or dissociate from proteins after internalization 3, 4 . Here, we report technology for covalent, specific tagging of cellular proteins with chemical probes. Through rational design, we redirected a microbial lipoic acid ligase (LplA) 5 to specifically attach an alkyl azide onto an engineered LplA acceptor peptide (LAP). The alkyl azide was then selectively derivatized with cyclooctyne 6 conjugates to various probes. We labeled LAP fusion proteins expressed in living mammalian cells with Cy3, Alexa Fluor 568 and biotin. We also combined LplA labeling with our previous biotin ligase labeling 7, 8 , to simultaneously image the dynamics of two different receptors, coexpressed in the same cell. Our methodology should provide general access to biochemical and imaging studies of cell surface proteins, using small fluorophores introduced via a short peptide tag.
Live cell imaging is a powerful method to study protein dynamics at the cell surface, but conventional imaging probes are bulky, or interfere with protein function 1,2 , or dissociate from proteins after internalization 3, 4 . Here, we report technology for covalent, specific tagging of cellular proteins with chemical probes. Through rational design, we redirected a microbial lipoic acid ligase (LplA) 5 to specifically attach an alkyl azide onto an engineered LplA acceptor peptide (LAP). The alkyl azide was then selectively derivatized with cyclooctyne 6 conjugates to various probes. We labeled LAP fusion proteins expressed in living mammalian cells with Cy3, Alexa Fluor 568 and biotin. We also combined LplA labeling with our previous biotin ligase labeling 7, 8 , to simultaneously image the dynamics of two different receptors, coexpressed in the same cell. Our methodology should provide general access to biochemical and imaging studies of cell surface proteins, using small fluorophores introduced via a short peptide tag.
Fluorescent labeling of cell surface proteins enables imaging of the trafficking and function of receptors, channels and transporters. Many protein labeling methods have been developed in recent years 9 , but none currently allows the covalent attachment of small fluorophores onto cell surface proteins modified only by a small peptide tag, with short labeling times and with extremely high specificity over a wide range of expression levels and labeling conditions. To address this shortcoming, we developed a protein labeling technique based on the Escherichia coli enzyme LplA 5 . In E. coli, LplA catalyzes the ATPdependent covalent ligation of lipoic acid to one of three proteins involved in oxidative metabolism (E2p, E2o and H-protein 5 ) (Fig. 1a,  top) . LplA naturally exhibits extremely high sequence-specificity, but previous work showing that the enzyme accepts octanoic acid, 6-thio-octanoic acid and selenolipoic acid in place of lipoic acid 5 suggests that the small-molecule binding site has considerable plasticity. To harness LplA for fluorescent labeling, we reengineered the system in three stages. First, through synthesis and testing of ten different substrate analogs, we discovered an alkyl azide substrate that can be efficiently used by wild-type LplA in place of lipoic acid. Once ligated to the target protein, the azide functional group can be selectively derivatized with any fluorescent probe conjugated to a cyclo-octyne reaction partner 6 (Fig. 1a) . Second, to create a minimally invasive tag to direct the ligation of the alkyl azide, we engineered, through iterative cycles of rational design, a 22-amino-acid replacement for LplA's natural protein substrates, which can be fused to the N or C terminus of any protein of interest. Third, we tested the specificity of LplA in mammalian cells and found no background labeling of endogenous proteins.
For the first stage of LplA engineering, we considered a range of small-molecule structures to replace lipoic acid. Direct ligation of a fluorophore would offer a simpler and shorter labeling procedure, but incorporation of a 'functional group handle' is more feasible due to the small size of the lipoate binding pocket, and it provides greater versatility for subsequent incorporation of probes with diverse structures. Many functional group handles have been used in chemical biology, including ketones, organic azides and alkynes 10 . Organic azides are the most suitable for live cell applications, because the azide group is both abiotic and nontoxic in animals and can be selectively derivatized under physiological conditions (without any added metals or cofactors) with cyclo-octynes, which are also unnatural 6 . To test if LplA could accept an azide substrate in place of lipoic acid, we synthesized a panel of alkyl azide carboxylic acids of varying lengths (Supplementary Fig. 1 and Supplementary Methods online), and tested them for ligation onto a 9-kDa lipoyl domain derived from the full-length E2p protein 11 , using a high-performance liquid chromatography (HPLC) assay. We also synthesized a series of alkyne carboxylic acids as additional probes of the lipoate binding pocket ( Supplementary Fig. 1 online) . All probes were incorporated by LplA to some degree, but the efficiency of ligation exhibited a clear length-dependence, with azide 7 giving the fastest kinetics (Fig. 1b) . Figure 1c shows the HPLC trace associated with azide 7 ligation to E2p, in addition to negative control reactions with LplA or ATP omitted. We collected the product peak (starred) from the top trace and analyzed it by mass spectrometry, which confirmed that one molecule of azide 7 had been site-specifically conjugated to E2p ( Supplementary Fig. 2 online) . We also measured the kinetics of azide 7 ligation to E2p (Supplementary Fig. 2 and Supplementary Methods online), and compared the values to those of lipoic acid ligation. The k cat values were only slightly different (0.111 ± 0.003 s -1 versus 0.253 ± 0.003 s -1 ) but the K m increased 75-or 30-fold for azide 7 (127 ± 11 mM) compared to lipoic acid (1.7 mM 5 or 4.5 mM 12 ). As seen below, it is straightforward and nontoxic to provide azide 7 at concentrations 4127 mM for live cell labeling, thus maximizing the rate of ligation.
For the second stage of engineering, we wished to design a peptide substrate for LplA to replace the known protein substrates. It was necessary for the peptide to be fully transposable (recognized when fused to the N-or C-terminal ends of any protein) and to be modified by LplA with similar efficiency to the natural protein substrates. We accomplished this through multiple rounds of rational design (Supplementary Fig. 3 online) . A major challenge was that E2p presents the lysine modification site at the tip of a sharp hairpin turn 13 , a conformation that is difficult to recapitulate in a peptide. Nevertheless, we designed an initial panel of seven peptides by analyzing lipoate acceptor proteins from different species, as well as structurally related biotin acceptor proteins. Peptides that were active in the initial screen were then improved through site-directed mutagenesis and tested for recognition at either terminus of a model protein. The final 22-aminoacid sequence, called the LplA acceptor peptide (LAP), had a k cat of 0.048 ± 0.001 s -1 (data not shown), only 2.3-fold lower than the corresponding k cat for full-length E2p ( Supplementary Fig. 2 online).
Our third task was to assess the specificity of LplA in mammalian cells. To do this, we created a LAP fusion to cyan fluorescent protein (CFP), and expressed it in human embryonic kidney (HEK) cells. HEK lysates were then labeled with LplA, azide 7 and ATP, and the ligated azide was detected by western blot analysis, after functionalization with a FLAG peptide through the Staudinger ligation 14 . In the presence of thousands of mammalian proteins in the cell lysate, only LAP-CFP is labeled by LplA (Fig. 2) . The expression level of LAP-CFP is so low that it cannot be seen above that of endogenous proteins in the Coomassie-stained gel. Negative controls with LplA replaced by a catalytically inactive mutant, or LAP-CFP replaced by an alanine point mutant at the lysine modification site, show that labeling depends on the presence of LplA and an intact LAP sequence. This experiment and the live cell labeling experiments described below demonstrate that LplA is a remarkably specific enzyme at the cell surface, and possibly within the cytosol as well.
To test in live cells our newly engineered small-molecule and peptide substrates for LplA, we first created an artificial construct by fusing LAP to CFP, and then fusing this in turn to the extracellular side of the transmembrane (TM) domain of the platelet-derived growth factor receptor (Fig. 3, top) . We also synthesized conjugates of our previously reported mono-fluorinated cyclo-octyne 6 (OCT) to two bright, red-emitting and membrane-impermeant fluorophores, Alexa Fluor 568 and Cy3 ( Supplementary Fig. 4 and Supplementary Methods online). Fig. 2 ). Labeling was accomplished by expressing LAP-CFP-TM in HEK cells, and adding 350 mM azide 7 in the presence of LplA for 1 h, followed by one of the fluorophore-OCT conjugates for 20 min. Transfected cells (indicated by CFP fluorescence) were labeled with Alexa Fluor 568 or Cy3, whereas neighboring untransfected cells in the same field of view were not labeled (Fig. 3) . Interestingly, labeling with Alexa Fluor 568 generated higher background than Cy3 labeling, because of faster nonspecific internalization of the probe. We performed additional negative controls with omission of azide 7 or replacement of LAP-CFP-TM by its alanine mutant, and observed no labeling in either case. Unlike sodium azide, organic azides, such as the clinically approved drug AZT 15 , are not known to be toxic to cells, but we nevertheless examined the effect of 24-h exposure to azide 7 on mitochondrial respiration, and found no effect at concentrations o750 mM (data not shown).
We also compared the speed, sensitivity and specificity of LplA labeling to two other previously described peptide-based labeling methods ( Supplementary Fig. 5 online) . Biotin ligase (BirA)/ketone tagging makes use of a ketone isostere of biotin, which can be functionalized with hydrazide conjugates after enzymatic ligation to proteins fused to a 15-amino-acid 'acceptor peptide' (AP) 16 . Transglutaminase labeling involves enzyme-mediated attachment of cadaverine-functionalized fluorophores to a glutamine-containing peptide recognition sequence 17 . For the comparison experiments, we used LplA to label LAP-CFP-TM with azide 7, followed by OCTbiotin, and followed by streptavidin-Alexa Fluor 568 to detect the biotin ( Supplementary Fig. 5 and Supplementary Methods online). A total labeling time of only 20 min was required for all three steps, and we obtained a signal-to-background ratio Z3:1. In contrast, BirA/ ketone labeling of an analogous AP-CFP-TM construct with a biotinhydrazide compound followed by streptavidin detection required 2 h and 15 min to achieve a similar signal-to-background ratio. We also quantified the sensitivity of LplA labeling using the wedge method 18 and determined that cells expressing as little as 5 mM LAP-CFP-TM could be specifically labeled with OCT-biotin, with a signal-to-background ratio Z3:1 (Supplementary Methods). Similar experiments demonstrated that LplA was also superior to transglutaminase, particularly in labeling specificity at higher enzyme concentrations (Supplementary Fig. 5 online) .
To illustrate the use of LplA labeling for imaging biological receptors, we created a LAP fusion to the low-density lipoprotein receptor (LDLR), which functions in the uptake of cholesterol in peripheral tissues of the body 19 . We established that LAP-LDLR could be labeled with OCT-Cy3 or OCTbiotin in HEK cells, even when expressed at levels matching those of endogenous LDLRs (data not shown). For many imaging studies, it is desirable to visualize two different receptors at once in the same cell to compare their distributions or trafficking patterns. To develop this capability, we investigated the compatibility of LplA labeling with BirA/streptavidin targeting. Unlike BirA/ketone labeling, BirA/streptavidin targeting 7, 8 makes use of site-specific biotin ligation onto AP-tagged proteins, followed by recognition with streptavidin-fluorophore conjugates. Whereas the use of streptavidin increases the total size of the label, the femtomolar affinity of the biotin-streptavidin interaction makes this labeling approach much faster and much more sensitive than BirA/ketone labeling 7 .
E. coli LplA and biotin ligase are mechanistically related, and their natural acceptor proteins share some structural and sequence overlap 20 . However, the engineered LAP and AP sequences are dissimilar, as are the azide 7 and biotin structures. To test the orthogonality of these two labeling methods, we prepared separate dishes of HEK cells expressing LAP-LDLR (with a GFP tag to serve as a transfection marker), or AP-EGFR (AP fused to the extracellular N terminus of the epidermal growth factor (EGF) receptor 16 ) together with a CFP transfection marker (Supplementary Methods). After 16À24 h of expression, the cells were replated together in a single dish. We performed labeling by first adding a mixture of LplA, BirA, azide 7, biotin and ATP to the cells. Thereafter, OCT-Cy3 was added to derivatize the azide, and streptavidin was added to detect the biotin. Cells expressing LAP-LDLR were selectively labeled with Cy3, whereas cells expressing AP-EGFR were selectively labeled with streptavidin ( Supplementary Fig. 6 online) . The same results were obtained using LAP-LDLR in combination with an AP-tagged receptor for ephrinA3 (AP-EphA3). Thus, simultaneous labeling of cells with LplA and BirA is possible, without sacrificing the high specificity of each system.
We then used this two-color labeling protocol to image LAP-and AP-fused receptors coexpressed within the same cell. EGFR and EphA3 are both known to function in cell migration 21, 22 , and thus we carried out imaging on cells migrating toward an artificial wound. HEK cells were cotransfected with either LAP-LDLR and AP-EGFR, or LAP-LDLR and AP-EphA3. After 16À24 h of expression, the confluent cells were wounded with a pipette tip. We allowed the wound to partially close over 12À18 h, and then performed simultaneous labeling with Cy3 and Alexa Fluor 488 conjugated to monovalent streptavidin 8 . Cy3-labeled LDLR was evenly distributed on the surface of the HEK cells, whereas Alexa Fluor 488-labeled EGFR and EphA3 were both asymmetrically concentrated at the leading edge of the polarized cells (Fig. 4) . The same patterns were also observed when the LAP and AP tags were swapped (AP-LDLR and LAP-EGFR), suggesting that the localization patterns do not reflect artifacts of AP and LAP tagging (data not shown).
Whereas the polarization of AP-EGFR to the leading edge of migrating cells is an expected result, and has previously been observed using antibody labeling 23 , the pattern of AP-EphA3 staining is surprising. Previous work has shown that trans interactions between EphA3 and ephrin ligand expressed on the surface of contacting cells play a role in developmental cell migration 24 and tumor invasion 25 . However, it is unclear what role unliganded EphA3 should play in migratory processes. Our observation of EphA3 accumulation at the free, leading edge of polarized cells suggests that unactivated EphA3 may function in cell signaling, or that EphA3 may be constitutively linked to the actin cytoskeleton.
In summary, we have developed a technology for labeling cell surface proteins fused to a 22-amino-acid recognition sequence for E. coli LplA. Small, non-cross-linking probes such as Cy3, Alexa Fluor and biotin can be conjugated site-specifically and covalently to the LAP peptide in as little as 20 min. An important feature of our technique is its generality; potentially a wide variety of cell surface proteins in diverse cell types can be labeled with a wide range of chemical probes linked to cyclo-octynes.
Many new protein labeling methods have been developed in recent years 9 , and a survey of these techniques reveals that a general trade-off exists between labeling specificity and tag size. Protein-based tags, such as SNAP/AGT 26 are generally more specific than peptide tags, such as FlAsH 27 . However, protein tags have greater potential to interfere with protein folding, trafficking and activity, as GFP often does 28, 29 . We and others (for instance, with Sfp/AcpS labeling methodology 30 ) have tried to bridge the requirements of small tag size and high labeling specificity, by making use of enzyme ligases. By capitalizing on the intrinsic sequence-specificity of enzymes such as biotin ligase and LplA, we can achieve highly specific probe conjugation, without sacrificing the small size of the directing tag.
In previous work with BirA, a ketone isostere of biotin could be accepted 16 , but compounds with more dissimilar structures, such as alkyne and azide derivatives of biotin, were not recognized by BirA due to structural requirements of the biotin binding pocket. In contrast, LplA exhibits much more relaxed specificity for its small-molecule substrate, while maintaining extremely high specificity for its protein or peptide substrate 5 . This property allows us to harness LplA for unnatural ligation reactions. The next important challenges will be to extend this technology to labeling of intracellular protein targets, and to reengineer LplA for one-step ligation of fluorophore or photoaffinity probes.
We also used LplA in combination with biotin ligase to differentially label two receptors expressed in the same cell. Many problems in receptor biology would benefit from simultaneous imaging of two or more different proteins in the same living cell, instead of separate experiments involving one-color labeling of each receptor. The combination of LplA and BirA tagging, which can be performed simultaneously due to the orthogonality of the reaction components, provides access to such experiments.
METHODS
In vitro LplA activity assays. LplA reactions contained 2 mM LplA, 200 mM E2p, 350 mM probe, 1 mM ATP, 2 mM magnesium acetate and 25 mM sodium phosphate pH 7.0. Reactions were incubated at 30 1C for 30 min, and then quenched with EDTA (final concentration 50 mM). Conversion to product was determined by HPLC on a C 18 reverse-phase column with a 40À57% gradient of acetonitrile in water with 0.1% trifluoroacetic acid over 20 min (flow rate 1.0 ml/min). Unmodified E2p had a retention time of B12 min, whereas E2p-probe conjugates eluted at 15À18 min. Percent conversion to product was calculated from the ratio of the E2p-probe peak area to the sum of (E2p + E2p-probe) peak areas. All measurements were performed in triplicate.
LplA specificity test on mammalian lysate. Human embryonic kidney (HEK) 293T cells were transfected with LAP-CFP-pcDNA3 plasmid using Lipofectamine 2000 (1 mg DNA/well of a 6-well plate). Lysates were generated 48 h later by hypotonic lysis to minimize protease release, as follows. Cells were lifted from the plates, concentrated by centrifugation and resuspended in 1 mM HEPES pH 7.5, 5 mM magnesium chloride, 1 mM phenylmethylsulphonyl fluoride and protease inhibitor cocktail (Calbiochem). After incubation at 4 1C for 10 min, the cells were lysed by vigorous vortexing for 2 min at 21 1C. Crude lysate was clarified by centrifugation, and stored at À80 1C. Lysate was labeled by incubating at 30 1C for 10 h with 25 mM sodium phosphate pH 7.0, 1 mM LplA, 250 mM azide 7, 1 mM ATP and 4 mM magnesium acetate. Thereafter, Staudinger ligation was performed by adding FLAGphosphine 14 to a final concentration of 500 mM, and incubating at 30 1C for 16 h. Each reaction sample was then divided into thirds. The first third was analyzed by 12% SDS-PAGE followed by western blotting with anti-FLAG(M2)-peroxidase antibody conjugate (Sigma, 1:1,000 dilution). The second sample was analyzed by 12% SDS-PAGE followed by Coomassie staining. The last third was analyzed by 12% SDS-PAGE without boiling the samples, to prevent unfolding of CFP, and in-gel fluorescence was visualized on a Storm 860 instrument (Amersham). 
